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Malaria parasites replicate within a parasitophorous vacuole (PV) in red blood cells (RBC). Progeny 27 
merozoites egress upon rupture of first the PV membrane (PVM) then poration and rupture of the RBC 28 
membrane (RBCM). Egress is protease-dependent1, but none of the effector molecules that mediate 29 
membrane rupture has been identified and it is unknown how sequential rupture of the two membranes 30 
is controlled. Minutes before egress, the parasite serine protease SUB1 is discharged into the PV2-6 where 31 
it cleaves multiple substrates2,5,7-9 including SERA6, a putative cysteine protease10-12. Here we show that 32 
Plasmodium falciparum parasites lacking SUB1 undergo none of the morphological transformations that 33 
precede egress and fail to rupture the PVM. In contrast, PVM rupture and RBCM poration occur normally 34 
in SERA6-null parasites but RBCM rupture does not occur. Complementation studies show that SERA6 is 35 
an enzyme that requires processing by SUB1 for its function. RBCM rupture is associated with SERA6-36 
dependent proteolytic cleavage within the actin-binding domain of the major RBC cytoskeletal protein -37 
spectrin. We conclude that SUB1 and SERA6 play distinct, essential roles in a coordinated proteolytic 38 
cascade that enables sequential rupture of the two bounding membranes and culminates in RBCM 39 
disruption through rapid, precise, SERA6-mediated disassembly of the RBC cytoskeleton. 40 
 41 
Malaria, caused by parasitic protozoa of the genus Plasmodium, causes over 400,000 deaths per 42 
annum. With widespread resistance to most antimalarial drugs, there is a need to better understand 43 
the biology of the parasite, especially the species responsible for most fatalities, Plasmodium 44 
falciparum. Asexual blood stage parasites proliferate within RBC. Following each cycle of intracellular 45 
development (lasting ~48 h in P. falciparum) the PVM and RBCM rupture to allow egress of merozoites 46 
which invade fresh RBC. 47 
Egress comprises several rapidly successive steps. Following biogenesis of intracellular 48 
merozoites by segmentation of the mature schizont, the PVM becomes permeable, allowing mixing of 49 
the contents of the PV and residual RBC cytoplasm6. Within the ensuing minutes, the parasite cGMP-50 
dependent protein kinase PKG is activated to trigger discharge of SUB1, a subtilisin-like protease, from 51 
merozoite secretory organelles called exonemes3,4. In the PV lumen, SUB1 proteolytically modifies 52 
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several merozoite surface and PV proteins2,5,7,8, including SERA6, which is cleaved to release a central 53 
domain with homology to papain-like (clan CA, family C1) cysteine peptidases10. Within ~10 minutes of 54 
SUB1 discharge, the PV abruptly swells whilst the entire infected RBC transforms from an irregular to a 55 
roughly spherical ‘flower’ or rounded-up structure13,14. The PVM then fragments into multilamellar 56 
vesicles, closely followed by collapse and poration (permeabilisation) of the RBCM6,14,15. Within seconds 57 
the RBCM ruptures, allowing merozoite release16. Inhibitors of PKG block SUB1 discharge and all stages 58 
of egress subsequent to the initial PVM permeabilisation step3,5,6,17. In contrast, the broad-spectrum 59 
cysteine protease inhibitor epoxysuccinyl-L-leucylamido(4-guanidino)butane (E64), which does not 60 
inhibit SUB1 activity3, prevents neither PVM rupture nor RBCM collapse and poration, but blocks the 61 
final step of RBCM rupture6,14,15,18. 62 
We used the rapamycin (RAP)-inducible dimerizable Cre recombinase (DiCre) system19,20 to 63 
conditionally excise either a segment of the SUB1 gene encoding crucial catalytic residues, or the entire 64 
SERA6 coding sequence (Fig. 1a). In each case, PCR (Fig. 1a) and Western blot (Fig. 1b and 65 
Supplementary Fig. 1) demonstrated rapid and efficient RAP-induced excision of the floxed DNA 66 
sequences and ablation of SUB1 or SERA6 expression. Immunofluorescence analysis (IFA) confirmed 67 
loss of SUB1 in 99.8% of schizonts (of 5,056 examined) by the end of the erythrocytic cycle (cycle 0) in 68 
which the parasites were RAP-treated (Fig. 1c). Both SUB1-null (SUB1) and SERA6 parasites formed 69 
morphologically normal schizonts at the end of cycle 0, showing that neither gene is required for 70 
intracellular development (Fig. 1c). However, over the ensuing erythrocytic cycles there was a dramatic 71 
reduction in replication rates of the RAP-treated cultures (Fig. 1d). Monitoring over 8-10 erythrocytic 72 
cycles showed that the initially minor population of non-excised parasites gradually overgrew these 73 
cultures whilst the SUB1 or SERA6 parasites disappeared (Fig. 1e), indicating a severe defect. To 74 
further assess the impact of gene disruption we used a plaque assay12 which captures successive rounds 75 
of replication by individual parasite clones. Substantial reductions in plaque numbers were observed in 76 
RAP-treated cultures (Fig. 1f and reference 12), and the few plaques generated were found to arise 77 
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from the small population of non-excised parasites (Supplementary Fig. 2 and reference 12). These 78 
results suggested that both the SUB1 and SERA6 genes are required for in vitro parasite growth. 79 
To confirm that loss of viability was a consequence of gene disruption, plasmids for episomal 80 
expression of wild-type (WT) SUB1 or SERA6 transgenes were introduced into the (non-RAP-treated) 81 
SUB1HA3:loxP or SERA6:loxP parasites respectively. The resulting lines were RAP-treated to disrupt the 82 
chromosomal genes, then immediately analysed by plaque assay in comparison with RAP-treated 83 
control lines harbouring ‘empty’ plasmid. As shown in Fig. 1f, lines carrying episomal WT SUB1 or SERA6 84 
transgenes produced significantly more plaques following disruption of the chromosomal genes than 85 
similarly-treated parasites harbouring empty plasmid. Parasites expanded from plaques produced by 86 
RAP-treated parasites carrying the episomal SUB1 or SERA6 transgenes had lost the respective 87 
chromosomal gene as expected and so were likely relying solely on the episomal gene copies 88 
(Supplementary Fig. 3). Crucially, the SERA6 growth defect could not be rescued by a mutant SERA6 89 
transgene possessing an Ala substitution of the predicted catalytic Cys644 codon (expected to ablate 90 
enzyme activity10) (Fig. 1f). Similarly, the SERA6 defect was not complemented by a SERA6 mutant in 91 
which the SUB1 processing sites flanking the papain-like domain were modified by Leu substitutions of 92 
the P1 and P2 residues upstream of each scissile bond; these mutations prevent SUB1-mediated 93 
cleavage10 (Fig. 1f). Collectively, these findings confirmed that SUB1 and SERA6 are indispensable and 94 
indicated that SERA6 is an enzyme that requires proteolytic processing by SUB1 to perform its function. 95 
To examine egress of SUB1 and SERA6 parasites, mature schizonts were incubated with the 96 
PKG inhibitor (4-[7-[(dimethylamino)methyl]-2-(4-fluorphenyl)imidazo[1,2-α]pyridine-3-yl]pyrimidin-2-97 
amine (compound 2; C2), which reversibly blocks development just prior to egress, resulting in 98 
accumulation of ‘stalled’ segmented schizonts. Wash-out of the inhibitor allows rapid progress to 99 
rupture, enabling live microscopic examination of multiple egress events over the ensuing ~10-30 100 
minutes3,5,9. As shown in Fig. 2a and Supplementary Movie 1, SUB1 parasites underwent none of the 101 
morphological changes associated with egress, with no signs of PVM swelling, rounding up, apparent 102 
PVM rupture (as indicated by loss of differential interference contrast and increased mobility of the 103 
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intracellular merozoites), or RBCM rupture. Indeed, the SUB1 phenotype was indistinguishable from 104 
that produced by continued incubation with C2, suggesting that SUB1 is required for all the egress-105 
related transformations that follow PKG activation. This egress defect was completely rescued by the 106 
WT SUB1 transgene (Supplementary Movie 2). As expected, proteolytic processing of the SUB1 107 
substrates SERA52, SERA6 and merozoite surface protein-1 (MSP1)5,7 was ablated in the SUB1 108 
parasites (Fig. 2b). However, IFA using antibodies to AMA1, a protein released onto the merozoite 109 
surface from micronemes (which are distinct from the exonemes in which SUB1 is stored2,3) showed 110 
that microneme discharge occurred in the trapped SUB1 merozoites (Fig. 2c). Like SUB1 discharge, 111 
AMA1 discharge is blocked by PKG inhibitors3, so this confirmed reversal of the C2-mediated PKG 112 
inhibition in these experiments. 113 
P. falciparum is generally maintained in static culture. To address whether invasion-competent 114 
merozoites could be liberated by fluid shear stress, SUB1HA3:loxP schizonts were cultured overnight 115 
with fresh RBC under vigorously shaking conditions. As expected21, shaking enhanced increases in 116 
parasitaemia in mock-treated SUB1HA3:loxP cultures (Fig. 2d), likely due to more efficient merozoite 117 
dissemination and RBC invasion. However, shaking had no impact on the low proliferation rate of RAP-118 
treated (SUB1) parasites, indicating that SUB1 is essential for release of invasive merozoites. 119 
In contrast to the SUB1 phenotype, SERA6 schizonts displayed normal rounding up as well 120 
as the increases in merozoite visibility and mobility thought to indicate PVM rupture; however, RBCM 121 
rupture did not occur (Fig. 2e and Supplementary Movie 3). Introduction of the complementing WT 122 
SERA6 expression plasmid restored egress (Supplementary Movie 4). IFA confirmed microneme 123 
discharge in theSERA6 schizonts (Fig. 2f) whilst Western blot revealed normal SUB1 activity (Fig. 2g). 124 
Similar to the SUB1 parasites, shaking did not enhance the replicative capacity of SERA6 parasites 125 
(Fig. 2h). 126 
Upon PVM lysis, but just prior to RBCM rupture, the RBCM suddenly becomes permeable to 127 
the F-actin binding peptide phalloidin9,14,22. To definitively establish the fate of the PVM in the mutants 128 
and to examine the timing and efficiency of RBCM poration, SUB1HA3:loxP and SERA6:loxP parasites 129 
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were transfected prior to RAP-treatment with a plasmid for constitutive expression of the PVM protein 130 
EXP123 fused to mCherry, fluorescently labelling the PVM (Supplementary Fig. 4). Simultaneous DIC and 131 
fluorescence video-microscopy in the presence of fluorescent wheat germ agglutinin (which labels the 132 
RBCM) and fluorescent phalloidin, confirmed that neither PVM rupture nor RBCM poration took place 133 
in SUB1 parasites (Fig. 3a and Supplementary Movie 5). In contrast, RBCM poration occurred normally 134 
in the SERA6 parasites upon PVM rupture. Examination of the arrested SUB1 parasites by 135 
transmission electron microscopy (TEM) confirmed an intact PVM and RBCM indistinguishable from C2-136 
arrested schizonts (Fig. 3b and Supplementary Fig. 5). In contrast, scanning EM (Fig. 3c) and TEM (Fig. 137 
3d and Supplementary Fig. 5) of arrested SERA6 parasites revealed merozoites and PVM fragments 138 
within an intact but collapsed and evacuated RBCM, as previously observed in WT parasites arrested 139 
by E646. 140 
Our observation that egress proceeded normally in the SERA6 parasites up to the point of 141 
RBCM rupture suggested that SERA6 mediates RBCM breakdown. To test this model and further dissect 142 
the SERA6 defect, we performed a proteomic comparison of mock- and RAP-treated SERA6:loxP 143 
schizonts. SDS PAGE (Fig. 4a) detected a high molecular mass species that appeared within 20 minutes 144 
in soluble fractions of mock-treated parasites allowed to undergo egress, identified as a truncated form 145 
of the major RBC cytoskeleton protein -spectrin. Further quantitative tandem mass spectrometry (LC-146 
MS/MS) analysis revealed the concomitant appearance of one or more lower molecular mass 147 
polypeptides comprising the N-terminal calponin homology (CH) domain of the -spectrin actin-binding 148 
domain (ABD) (Fig. 4b and Supplementary Fig. 6). This suggested that RBCM rupture is associated with 149 
proteolytic cleavage of -spectrin near its N-terminus and release of the cleavage products from the 150 
cytoskeleton (which is generally insoluble in aqueous buffers). Western blot (Fig. 4c) and pull-downs 151 
using spectrin-specific monoclonal antibodies (mAbs) combined with LC-MS/MS (Fig. 4d and 152 
Supplementary Fig. 7) confirmed and extended this, showing that RBCM rupture is accompanied by 153 
extensive SERA6-dependent cleavage of -spectrin at two closely-spaced sites (Gln167-Glu168 and 154 
Gln165-Thr166) between the CH1 and CH2 domains of the ABD, releasing the CH1 domain as a ~17 kDa 155 
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fragment and resulting in solubilisation of the truncated -spectrin along with some -spectrin. The 156 
released CH1 domain co-purified with human -actin, likely also derived from the RBC cytoskeleton 157 
(Fig. 4d and Supplementary Fig. 8). No proteolytic cleavage of the other major RBC cytoskeletal 158 
components -spectrin and protein 4.1R was detectable, although limited SERA6-dependent cleavage 159 
of ankyrin was evident (Supplementary Fig. 9). Strikingly, -spectrin cleavage was never observed in 160 
SERA6 parasites, even upon mechanical, hypotonic, freeze-thaw or detergent-mediated rupture of 161 
the schizonts (Fig. 4e), showing that cleavage was not due to lysis per se and implicating SERA6 as the 162 
enzyme responsible. The -spectrin CH1 domain mediates key interactions between each end of the 163 
-spectrin tetramers that constitute the bulk of the cytoskeleton, and short -actin filaments 164 
(together with protein 4.1R) at the junctional complexes that link the RBC cytoskeleton to its plasma 165 
membrane, providing the latter with structural integrity (Fig. 4f)24-26. Cleavage is therefore predicted to 166 
unravel the cytoskeleton with resulting RBCM destabilisation (Fig. 4g). Spectrin tetramers also bind the 167 
plasma membrane through interactions with the ankyrin complex24, so the limited cleavage of ankyrin 168 
might facilitate release of the cleavage products and associated proteins from the cytoskeletal complex.  169 
Our findings ascribe the physico-mechanical processes underlying malarial egress to two 170 
parasite proteases that act rapidly and sequentially within the same, PKG-regulated pathway. SUB1 is 171 
required for all the structural changes following PKG activation, including rounding up, PVM lysis, RBCM 172 
poration and RBCM rupture. SERA6 is not required for PVM rupture or RBCM poration, but 173 
accomplishes the final step of RBCM rupture primarily through targeted cleavage of -spectrin at a site 174 
that is essential for cytoskeletal stability. PVM rupture is unlikely to be directly mediated by protease 175 
activity, so SUB1 may regulate this by activating one or more membrane lytic effectors that mediate 176 
PVM rupture, as well as perhaps RBCM poration. These could include pore-forming proteins or 177 
phospholipases, both implicated in egress of other parasite developmental stages22,27,28. That SERA6 178 
function requires SUB1-mediated processing is consistent with processing representing activation of 179 
SERA6, as previously suggested10. The striking similarity between the SERA6 phenotype and that 180 
produced by treatment with E646,14,18 supports this and suggests that SERA6 is the major target of E64 181 
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in schizonts. Importantly, our study proves that host RBC calpain-1, previously implicated by others in 182 
egress29, is not sufficient for RBCM rupture since its expression should be unmodified in SERA6 183 
parasites. 184 
All Plasmodium species, including the other major pathogens P. vivax and P. knowlesi, express 185 
orthologues of SUB1 and SERA6. Drugs that inhibit these proteases, particularly if combined with 186 
inhibitors of PKG30, would target consecutive, interdependent steps in the egress pathway and so could 187 
form a new class of antimalarial designed to prevent parasite proliferation and disease.  188 
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Methods 189 
Reagents and antibodies 190 
Anonymised human blood was obtained from the UK National Blood Transfusion Service. The antifolate 191 
WR99210 was from Jacobus Pharmaceuticals (New Jersey, USA). Blasticidin, rapamycin and E64 (Sigma) 192 
were used as described previously9,19. Compound 2 was kindly provided by Dr Simon Osborne (LifeArc, 193 
SBC Open Innovation Campus, Stevenage UK); stocks (10 mM) were stored in DMSO at -20oC and used 194 
throughout at a final concentration of 1 M. Alexa Fluor 488 phalloidin and Alexa Fluor 647-conjugated 195 
WGA was from Thermofisher. The -spectrin-specific mAbs B-1, B-2 and VD4, the -spectrin-specific 196 
mAb 17C7, and mAbs B-11 and 8C3 specific for protein 4.1R and ankyrin respectively were all from 197 
Santa Cruz Biotechnology. Monoclonal antibody 7.7 (anti-EXP2) was from the European Malaria 198 
Reagent Repository (http://www.malariaresearch.eu/), contributed by Jana McBride. The polyclonal 199 
anti-mCherry antibody (ab167453) was from Abcam. The P. falciparum MSP1-specific mAb 89.1 has 200 
been described previously31, as have rabbit antisera to P. falciparum SERA59, SERA610, SUB132 and 201 
AMA133. Phusion high-fidelity DNA polymerase and restriction enzymes were from New England 202 
BioLabs, and a Rapid DNA Ligation Kit (Roche) was used for DNA ligation. 203 
 204 
Parasite maintenance, synchronization and transfection 205 
The DiCre-expressing P. falciparum clone 1G5DC19 was maintained at 37°C in human RBC in RPMI 1640 206 
medium containing Albumax (Invitrogen) supplemented with 2 mM L-glutamine. Cultures were 207 
routinely monitored by microscopic examination of Giemsa-stained thin blood films and synchronised 208 
by standard procedures34. As required, mature schizonts were isolated by centrifugation over cushions 209 
of 70% (v/v) isotonic Percoll (GE Healthcare Life Sciences) as described34. Invasion assays were 210 
performed as previously described3,5, either in static culture or in a shaking incubator revolving at 225 211 
rpm. For transfection of plasmid constructs, ~108 Percoll-enriched schizonts were suspended in 100 l 212 
of P3 primary cell solution containing 10 g of DNA and electroporated with an Amaxa™ P3 primary cell 213 
4D Nucleofector™ X Kit L (Lonza), using program FP158 as previously described5. Growth medium was 214 
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supplemented ~20 h post transfection with WR99210 (2.5 nM) or blasticidin (2 g/ml). Once sustained 215 
growth of drug-resistant parasites was observed, drug cycling was used to enrich for genomic 216 
integration of plasmid constructs as previously described2. Transgenic parasite clones SUB1HA3:loxP 217 
and SERA6:loxP were obtained by limiting dilution cloning in microplates at a 0.1-0.3 parasite per well. 218 
Parasite genomic DNA (gDNA) for genotype analysis was extracted using a Qiagen DNeasy Bood and 219 
Tissue kit and analyzed by PCR using Kappa 2G Fast HotStart ReadyMix (Kappa Biosciences). 220 
 221 
Immunofluorescence and Western blot  222 
For IFA, air-dried thin films of parasite cultures were fixed in paraformaldehyde, permeabilized, then 223 
probed with relevant primary antibodies as described previously10. Secondary Alexa Fluor 488- or 594-224 
conjugated antibodies specific for human, rabbit or mouse IgG (Invitrogen), or Alexa Fluor 594-225 
conjugated streptavidin (Invitrogen) were used at a dilution of 1:1000. Samples were mounted in 226 
Vectashield antifade mounting medium (Vector Laboratories) containing DAPI. Images were acquired 227 
using a Nikon Eclipse and NIS Elements software (Nikon, Japan), using identical exposure conditions for 228 
all samples being compared. Western blots were performed as described previously33. For detection of 229 
HA3-tagged SUB1, the rat anti-HA mAb 3F10 (Sigma) was used at a 1:1000 dilution, followed by biotin-230 
conjugated anti-rat antibody (Roche) (1:8,000 dilution), then horseradish peroxidase (HRP)-conjugated 231 
streptavidin (Sigma) (1:10,000 dilution). Immobilon Western Chemiluminescent HRP Substrate 232 
(Millipore) was used according to the manufacturer’s instructions, and blots were visualised and 233 
documented using a ChemiDoc Imager (Bio-Rad) with Image Lab software (BioRad). 234 
 235 
Generation of integration, complementation and expression plasmids 236 
SUB1HA3:loxP and SERA6:loxP parasite clones were generated by single crossover homologous 237 
recombination into the 1G5DC genome using integration plasmids pHH1_SUB1HA3_loxP and 238 
pHH1_S6chimera_loxP respectively. In both cases, correct transcriptional regulation of the modified 239 
gene was assured by placement of the 3’ UTR of the P. berghei dihydrofolate reductase thymidylate 240 
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synthase (PbDT) gene downstream of the floxed coding sequence19. To target the SUB1 gene, a chimeric 241 
gene fragment with a native 5’ portion and a recodonised 3’ segment was constructed by first 242 
amplifying the 5’ sequence from P. falciparum 3D7 gDNA using primers JT-S1endo-F and JT-S1CO-R, 243 
whilst the recodonised region was amplified from plasmid pFastBac-sPfSUB1wt32 using primers JT-244 
S1CO-F and JT-S1synth-R. The amplicons were then fused in frame by inclusion of both in a fresh PCR 245 
reaction including primers JT-S1endo-F and JT-S1synth-R, and the product cloned into pGEM-T 246 
(Promega). A segment of this fragment was then excised using HindIII and KpnI and replaced with a 247 
similarly-digested loxP-containing synthetic intron (loxPint)20 (Geneart). This intermediate vector was 248 
digested with HpaI and Xho I to liberate the SUB1 sequence which was ligated into pHH1_sera5_LoxP119 249 
digested with the same enzymes to generate  pHH1_SUB1HA3_loxP. Integration of this construct into 250 
the 1G5DC SUB1 locus by homologous recombination was detected by diagnostic PCR with primers 251 
JT111-1p and JT111-2p, and the floxed or excised SUB1 locus was detected by PCR using primers JT111-252 
1p and JT111-3p. 253 
To generate pHH1_S6chimera_loxP, a chimeric SERA6 gene fragment was excised from plasmid 254 
MWS36 by digestion with HpaI and NcoI. Full details of plasmid MWS36 will be provided in a separate 255 
manuscript (M. Shea and M. Blackman, in preparation). The chimeric SERA6 sequence comprised a 920 256 
bp  5’ portion of endogenous coding sequence starting from within the first intron followed by synthetic 257 
recodonised SERA6 cDNA sequence extending to the stop codon. Plasmid pHH1_sera5_LoxP1 was 258 
digested with HindIII, ‘blunted’ with T4 DNA polymerase, then further digested with NcoI before ligation 259 
to the chimeric SERA6 fragment excised from MWS36, generating pHH1_S6chimera_loxP. Integration 260 
of this construct by homologous recombination into the 1G5DC genome (which already contains a 261 
single genomic loxP site upstream of the SERA6 locus19) was designed to introduce a second loxP site 262 
downstream of the SERA6 stop codon. Correct integration was detected by diagnostic PCR using 263 
primers SERA6-5’UTRb and SERA6-37, whilst the floxed or excised SERA6 locus was detected with 264 
primers S65’UTRb-2 and S6EndoEx2Rev. 265 
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For generation of plasmid constructs designed for transgenic expression of SERA6, a chimeric 266 
coding sequence and native SERA6 promoter was excised from plasmid MW28 and ligated into SalI and 267 
NcoI digested plasmid pDC-mCherry-MCS (a modification of pDC2-mCherry9), giving rise to pDC2-268 
wtSERA6 (WT SERA6). The chimeric SERA6 sequence comprised 979 bp of putative promoter sequence 269 
upstream of the native SERA6 ATG start codon, as well as  477 bp of the 5’ segment of the coding 270 
sequence (including the first intron) and a synthetic recodonised SERA6 cDNA10 encoding the remainder 271 
of the ORF. Full details of plasmid MWS28 will be provided in a separate manuscript (M. Shea and M. 272 
Blackman, in preparation). Site-directed mutagenesis and sub-cloning steps were then used as 273 
previously described10 to generate identical constructs containing di-Leu substitutions of the P1 and P2 274 
positions at the SUB1 processing sites 1 and 2 in SERA6,  as well as a Cys644Ala substitution of the active 275 
site nucleophile, giving rise to plasmids pDC2-SERA6-uncleavable (Uncleavable SERA6) and pDC2-276 
SERA6_Alamut  (Cys644Ala) respectively. 277 
For transgenic expression of WT SUB1 the pDC-mCherry-MCS plasmid was modified such that 278 
the blasticidin deaminase (BSD) drug selection cassette and mCherry reporter gene were expressed 279 
from a single promoter by the use of the ribosomal T2A skip peptide. To do this, the BSD cassette was 280 
excised from pDC2-mCherry_MCS with ApaI and SacI and the backbone re-ligated. The mCherry ORF 281 
was then excised by digestion with AvrII and XhoI and replaced with a synthetic gBlock (IDT) 282 
comprising the mCherry and BSD ORFs separated by the T2A sequence. This resulted in construct pDC2-283 
mCherryT2ABSD_MCS in which these ORFs remained under control of the constitutive P. falciparum 284 
calmodulin (CAM) promoter (which remained from the original mCherry expression cassette). This 285 
vector was then linearized with SnaBI. The P. falciparum SUB1 promoter sequence was amplified from 286 
P. falciparum 3D7 gDNA using primers PfSUB1_prom_for_infu and PfSUB1_prom_rev_infu. Primers 287 
PfSUB1_synth_for_infu and PfSUB1_synth_rev_infu were used to amplify the recodonised synthetic 288 
SUB1 ORF from pFastBac-sPfSUB1wt and primers PbDT3UTR-for_infu and PbDT3UTR-for_infu were 289 
used to amplify the PbDT 3’ UTR from pDC2-mCherry_MCS. Primers included complementary 290 
overhangs such that all 3 fragments could then be finally assembled into the  linearized pDC2-291 
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mCherryT2ABSD_MCS backbone in a single step using an InFusion HD Cloning Kit (Clontech), 292 
generating pDC2-mCherryT2ABSD_wtSUB1 (WT SUB1). 293 
For episomal transgenic expression of an EXP1mCherry fusion protein (to fluorescently label 294 
the PVM), a synthetic intronless DNA fragment encoding mCherry fused to the C-terminus of the P. 295 
falciparum EXP1 (PlasmoDB ID PF3D7_1121600) via a polyglycine-alanine linker (GAGGGGGGGGA) was 296 
obtained from Geneart. This was sub-cloned into vector pCR-Blunt using the ZeroBlunt PCR cloning kit 297 
(Invitrogen). The resulting plasmid was digested with AvrII and XhoI before ligating the EXP1mCherry 298 
fragment into pDC-mCherry-MCS in the place of the mCherry ORF, generating pDC2-EXP1-mCherry.  299 
 300 
Parasitaemia quantitation by flow cytometry 301 
Parasites were fixed in 4% paraformaldehyde, 0.02% glutaraldehyde for 30 min at 37C, diluted five-302 
fold in phosphate-buffered saline, then stored at 4C until required. Cells were stained with Hoechst 303 
33342 (diluted 1:10,000) for 30 min at 37C, then parasitaemia determined using a Fortress or FACS 304 
Aria (BD) flow cytometer as previously described9. Briefly, samples were initially screened using forward 305 
and side scatter parameters and gated for RBC (Supplementary Fig. 10). Ultraviolet light with a violet 306 
filter (450/50 nm) was then used  to determine the proportion of infected cells in 100,000 RBC. 307 
 308 
Time-lapse DIC and fluorescence video microscopy 309 
Viewing chambers for live microscopy were constructed as described previously3,5 by adhering 22 x 64 310 
mm borosilicate glass coverslips to microscope slides. Mature Percoll-enriched schizonts were 311 
incubated for 3-4 h at 37°C in complete medium supplemented with C2 (1 M), then ~5 x 107 schizonts 312 
were rapidly washed twice in gassed warm complete medium lacking C2, pelleting at 1,800 x g for 1 313 
min. The cells were suspended in 50 μl of the same medium and introduced into the pre-warmed 314 
viewing chamber on a temperature-controlled microscope stage held at 37oC on a Nikon Eclipse Ni-E 315 
wide-field microscope fitted with a Hamamatsu C11440 digital camera and Nikon N Plan Apo  316 
100x/1.45NA oil immersion objective. Images (DIC alone or simultaneous DIC and fluorescence) were 317 
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taken at 5-10 s intervals over a total of 20-60 min, then annotated and exported as TIFFs, AVI or 318 
QuickTime movies using  Nikon NIS-Elements software.  319 
 320 
Parasite plaque assays 321 
Plaque assays were performed by dispensing parasite cultures (200 l at a haematocrit of 0.75%) into 322 
flat-bottomed 96-well microplates, as described12. Plates were imaged 14-16 days later to detect 323 
plaque formation, using an Epson Perfection V750 Pro high resolution flat-bed scanner in top-down 324 
transmission light mode. When required, parasites from wells containing a single plaque were 325 
expanded by transferring initially to round-bottomed microplate wells to aid medium changes, before 326 
further expansion into culture flasks. 327 
 328 
Scanning electron microscopy 329 
Mature arrested SERA6 schizonts, or WT control schizonts allowed to reach the point of egress in the 330 
presence of E64 (50 M) were fixed in 2.5% glutaraldehyde, washed, osmicated (1% OsO4 for 16 h), 331 
dehydrated, critical point dried and sputter coated with 5 nm gold for scanning EM. Images were 332 
collected on a JEOL JSM 7610F with 2.6 kV accelerating voltage. 333 
 334 
Transmission electron microscopy 335 
Mature schizonts were fixed for 5 min at 37oC in 2% formaldehyde (SERA6 and E64-arrested schizonts) 336 
or 2% formaldehyde 1% glutaraldehyde (SUB1 and C2-arrested WT schizonts), pelleted by 337 
centrifugation, mixed with 20% (w/v) dextran in complete medium containing bakers’ yeast, then 338 
frozen using a HPM100 high-pressure freezer (Leica). Vitrified cells were freeze-substituted using a EM 339 
AFS2 (Leica) into Lowicryl HM20 resin (EMS) with 0.2% (w/v) uranyl acetate and cut into 250 nm or 120 340 
nm sections using a UC7 microtome (Leica). Sections were placed on glow-discharged carbon-coated 341 
copper London Finder grids (EMS) with 10 nm Protein A-Au fiducials (EMS) and post-stained with 0.2% 342 
(w/v) uranyl acetate and 4% (w/v) lead citrate. Images and tomograms were recorded using a Model 343 
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2040 dual-axis tomography holder (Fischione Instruments) on a Tecnai F20 200 kV field emission gun 344 
electron microscope (FEI) equipped with a DE20 camera (Direct Electron), or a Tecnai T12 120 kV field 345 
emission gun electron microscope (FEI) equipped with a 4kx4k Ultrascan 4000 CCD camera (Gatan). 346 
Dual-axis tilt series were acquired from -60 to +60 with an increment of 2 using SerialEM35 and 347 
processed using IMOD36 with nonlinear anisotropic diffusion filtering. 348 
 349 
Proteomic analysis and pull-downs 350 
Mature mock- or RAP-treated mature SERA6:loxP schizonts were incubated for ~4 h at 37°C in complete 351 
medium supplemented with C2, then washed once in gassed, warm protein-free medium containing 352 
C2 before rapidly washing twice in similar medium lacking C2, pelleting at 1,800 x g for 1 min. The cells 353 
were suspended at high density (~1 x 109/ml) in warm protein-free medium lacking C2 and incubated 354 
for just 20 min at 37°C to allow progress to egress. The entire samples were then snap-frozen in liquid 355 
N2.  356 
For global proteomic analysis, samples were thawed by the addition of an equal volume of ice-357 
cold water containing protease inhibitors (cOmplete™ Protease Inhibitor Cocktail, Sigma-Aldrich), 358 
followed by centrifugation at 16,000 × g for 10 min at 4°C to separate soluble and insoluble fractions. 359 
These were immediately fractionated by SDS PAGE on NuPAGE 4-12% Bis-Tris gels (Invitrogen). Gels 360 
were stained with Quick Blue Coomassie (Triple Red) then the entire gel cut into 24 equally-sized slices 361 
and proteins in excised slices subjected to tryptic digestion37. LC-MS/MS analysis was as described 362 
below.  363 
For pull-down analysis, frozen schizont preparations were thawed in the presence of 1% (v/v) 364 
Nonidet® P40 (CAS 68412-54-4, Santa Cruz Biotechnology), 10 mM EDTA and protease inhibitors 365 
(cOmplete™ Protease Inhibitor Cocktail, Sigma-Aldrich) and extracted at 4°C for 1 h with intermittent 366 
vortexing.  The extracts were clarified by centrifugation at 16,000 × g for 10 min at 4°C, filtered through 367 
0.22 m PVDF centrifugal filter units (MilliporeSigma), then incubated with ~2 g of the relevant anti-368 
spectrin mAb for 1.5 h at 4°C with gentle mixing. Precipitation of immune complexes with Protein G 369 
16 
 
Sepharose™ 4 Fast Flow (GE Healthcare) followed the manufacturer’s protocol. Bound complexes were 370 
subjected to SDS PAGE and stained bands of interest excised and analysed by tryptic digestion and LC-371 
MS/MS. 372 
 373 
Mass spectrometry (LC-MS/MS) 374 
Tryptic digests were chromatographically resolved using an Ultimate 3000 RSLCnano (Dionex) with an 375 
EASY-Spray column (2 m particle size, PepMap C18, 100 Å pore size, 50 cm x 75 m ID; Thermo 376 
Scientific). Spectra were acquired using an LTQ Orbitrap Velos mass spectrometer (Thermo Scientific) 377 
acquiring the top 10 most intense ions in data dependent acquisition mode with CID fragmentation at 378 
35% normalised collision energy. For targeted work, data were acquired using an Orbitrap Fusion Lumos 379 
Tribrid mass spectrometer (Thermo Scientific) using a mixture of data dependent fragmentation and 380 
three targeted fragmentations (545.3006 Da, 659.8537 Da and 830.9363 Da for peptides FQIQDIVVQ, 381 
FQIQDIVVQTQ and FQIQDIVVQTQEGR, respectively) over a 3 sec cycle time. Dynamic exclusion was 382 
employed throughout to prevent repeat sampling of data dependent fragmentation. 383 
Data were searched using Mascot (Matrix Science) against the UniProt database, using trypsin 384 
or semi-trypsin as the cleavage enzyme, with a fixed carbamidomethylation modification (+57.021 Da) 385 
and variable methionine oxidation (+ 15.994 Da). A 10 ppm mass tolerance filter was applied for 386 
peptides with charge states +2 or above. Mascot search results were imported into Skyline38 to 387 
generate a spectral library for further quantitative processing of -spectrin peptides. 388 
 389 
Statistical analysis  390 
Prism 7 (GraphPad) was used for all statistical analysis. All experiments were performed at least twice, 391 
and statistical analysis was carried out by unpaired t-test of biological replicate or triplicate 392 
experiments. A p value of <0.05 was considered statistically significant. 393 
 394 
 395 
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Data availability 396 
The data supporting the findings of this study are available within the paper and its Supplementary 397 
Information and are also available from the corresponding authors upon request.  398 
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Figure legends. 399 
Figure 1.  SUB1 and SERA6 are essential for asexual blood stage P. falciparum growth. a,  Architecture of 400 
floxed loci in SUB1HA3:loxP and SERA6:loxP parasites. Introduced loxP sites (arrowheads), recodonised 401 
sequence (hatched), HA3 epitope and known (SUB1) or predicted (SERA6) catalytic residues are 402 
indicated. Outcomes of rapamycin (RAP)-induced DiCre-mediated excision and positions of primers 403 
(half arrows) used for diagnostic PCR are indicated (see Supplementary Table 1 for primer sequences). 404 
Insets, PCR (representative of 4 independent experiments) confirming efficient gene excision by the 405 
end of cycle 0, ~44 h following mock-treatment (-RAP) or RAP-treatment (+RAP) of ‘ring’-stage 406 
parasites. b, Western blots (representative of 2 independent experiments) showing ablation of SUB1 407 
and SERA6 expression in cycle 0 schizonts. c, Light microscopic and IFA images of mature cycle 0 408 
schizonts, showing normal parasite development and RAP-induced loss of SUB1HA3 expression 409 
(representative of 6 independent experiments). Loss of SERA6 expression could not be similarly 410 
confirmed by IFA due to C-terminal tagging of SERA6 being unsuccessful and the lack of suitable SERA6-411 
specific antibodies. Scale bar, 5 m. DAPI, 4,6-diamidino-2-phenylindole. d, Replication of mock- and 412 
RAP-treated SUB1HA3:loxP and SERA6:loxP parasites over 2 erythrocytic cycles. Parasitaemia values 413 
(quantified by FACS) are averages from 2 biological replicates in different blood sources. Error bars, 414 
±SD. e, PCR showing loss of SUB1 (1 experiment) and SERA6 (representative of 2 independent 415 
experiments) parasites and outgrowth of non-excised parasites upon extended passage of RAP-treated 416 
cultures. f, Dot plots showing relative plaque forming ability (ratio of plaque numbers produced by RAP-417 
treated cultures to those produced by mock-treated cultures, x100) of SUB1HA3:loxP and SERA6:loxP 418 
parasites without or following transfection with the indicated episomal expression plasmids. Statistical 419 
significance was determined by two-tailed t-test: SUB1HA3:loxPint: Empty vs WT 420 
complementation (t=7.702, d.f.=2, p=0.0164, 95% CI 4.636 to 16.73) n=2. SERA6:loxP: Empty vs WT 421 
complementation (t=19.65, d.f.=2, p=0.0026, 95% CI 68.39 to 107) n=2;  WT vs Cys644Ala 422 
complementation (t=30.96, d.f.=4, p<0.0001, 95% CI -94.44 to -78.81 ) n=3; WT vs Uncleavable 423 
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complementation (t=13.8, d.f.=4, p=0.0002, 95% CI -98.14 to -65.25) n=3. In all plots, central horizontal 424 
bar, mean. Error bars, ±SD. Significance levels: p≤0.001, ***; p≤0.01, **; p≤0.05, *.  425 
  426 
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Figure 2. SUB1 and SERA6 play distinct, sequential roles at egress. a, Left, stills from time-lapse DIC 427 
microscopic examination of control (-RAP) and RAP-treated (SUB1) SUB1HA3:loxP schizonts following 428 
removal of C2; elapsed time indicated. Scale bar, 20 m. Right, quantitation of PVM rupture in control 429 
and RAP-treated SUB1HA3:loxP schizont populations, collated from 5 videos of each from 2 430 
independent experiments (total number of observed PVM rupture events in control parasites, 226). 431 
PVM rupture is normalised to that in the controls (100% egress). Statistical significance determined by 432 
two-tailed t-test: -RAP vs +RAP (t=13.84, d.f.=2, p=0.0052, 95% CI -113.2 to -59.5); p≤0.01, **. b, 433 
Processing of SUB1 substrates is ablated in SUB1 parasites. Western blot of C2-blocked SUB1HA3:loxP 434 
schizonts, or 30 min after washing away C2. Processed forms of SUB1 substrates are arrowed. c, 435 
Microneme discharge in SUB1 parasites. IFA of C2-arrested parasites compared to 30 min after 436 
washing away C2. Translocation of AMA1 to the intracellular merozoite surface is evident in the washed 437 
parasites. Scale bar, 10 m. d, Invasion by control and RAP-treated SUB1HA3:loxP parasites under static 438 
and shaking conditions. Statistical significance by two-tailed t-test: -RAP stationary vs -RAP shaking 439 
(t=5.233, d.f.=5, p=0.0034, 95% CI 2.666 to 7.813 ) n=4;  +RAP start vs +RAP stationary (t=1.722, d.f.=5, 440 
p=0.1456, 95% CI -0.04104 to 0.2077) n=4; +RAP stationary vs +RAP shaking (t=0.4585, d.f.=5, 441 
p=0.6658, 95% CI -0.641 to 0.9193) n=4. Results shown are from 4 biological replicate experiments 442 
(some dots are overlaid). e, Left, time-lapse DIC microscopic stills of control and RAP-treated SERA6:loxP 443 
schizonts following C2 removal. Scale bar, 20 m. Right, quantitation of RBCM rupture. Data collated 444 
from 8 videos each of control and RAP-treated parasites, from 3 independent experiments (total 445 
number of observed rupture events in control parasites, 568). RBCM rupture is normalised to that in 446 
the controls (100% egress). Statistical significance  by two-tailed t-test: -RAP vs +RAP (t=25.39, d.f.=4, 447 
p<0.0001, 95% CI -95.07 to -76.33) n = 3; p≤0.001, ***. f, Microneme discharge in arrested SERA6 448 
parasites. IFA of C2-arrested parasites compared with 30 min after washing away C2. g, Disruption of 449 
the SERA6 gene has no effect on processing of SUB1 substrates. h, Invasion efficiencies of the SERA6 450 
parasites under static and shaking conditions. Statistical significance by two-tailed t-test: -RAP 451 
stationary vs -RAP shaking (t=5.674, d.f.=4, p=0.0048, 95% CI 2.57 to 7.496) n=3; +RAP start vs +RAP 452 
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stationary (t=2.741, d.f.=4, p=0.0518, 95% CI -0.004807 to 0.7581) n=3; +RAP stationary vs +RAP 453 
shaking (t=2.526, d.f.=4, p=0.0649, 95% CI -0.1348 to 2.855) n=3; p≤0.01, **. Results shown are from 3 454 
biological replicate experiments. In all plots, central bar, mean. Error bars, ±SD. Experiments in panels 455 
b, c, f and g were repeated twice, with reproducible results. 456 
 457 
Figure 3. SUB1 is required for PVM disruption and RBCM poration, whereas the SERA6 phenotype 458 
mimics egress arrest with the cysteine protease inhibitor E64. a, Stills from simultaneous time-lapse DIC 459 
and fluorescence microscopic examination of typical control WT, SUB1 and SERA6 schizonts at the 460 
indicated intervals following removal of the egress inhibitor C2. PVM rupture and RBCM poration 461 
(indicated by access of phalloidin to the host RBC cytoskeleton) occurs in the SERA6 parasites but not 462 
in the SUB1 parasites, whilst RBCM rupture occurs in neither mutant.  Scale bar, 10 m. b, TEM 463 
micrographs of an arrested SUB1 schizont and a C2-arrested control cell, showing that the trapped 464 
merozoites are surrounded in both cases by an intact PVM and RBCM. Knob structures characteristic 465 
of the parasite-infected RBCM6 are indicated on its outer surface (arrow heads). The black dots are gold 466 
fiducials added for tomography. Scale bar, 500 nm. c, SEM images of SERA6 schizonts before and 30 467 
min following C2 removal, showing collapse of the RBCM around the intracellular merozoites in the 468 
washed sample. Scale bar, 5 m. d, TEM micrographs of an arrested SERA6 schizont and an E64-469 
arrested control cell, showing in both remnants of ruptured PVM (asterisks) adjacent to the trapped 470 
merozoites. Knobs are highlighted as above (arrow heads). Scale bar, 500 nm. All experiments were 471 
repeated twice, with reproducible results. 472 
 473 
Figure 4. RBCM rupture is associated with rapid, SERA6-dependent cleavage of host RBC cytoskeleton -474 
spectrin within its actin-binding domain. a, SDS PAGE showing appearance upon egress of mock-treated 475 
(-RAP) SERA6:loxP schizonts of a high molecular mass species identified by Western blot and LC-MS/MS 476 
as truncated -spectrin (reproducible in 15 independent experiments). b, Peptides (red) identified by 477 
LC-MS/MS (3 technical replicate runs from a single biological experiment) of tryptic digests of 478 
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polypeptide(s) enriched in the mock-treated SERA6:loxP schizont extract in the indicated region of the 479 
gel (~15-20 kDa), indicating egress-associated, SERA6-dependent cleavage of -spectrin. A semi-tryptic 480 
peptide likely representing the C-terminus of the polypeptide(s) is in bold (Supplementary Fig. 6 shows 481 
fragmentation spectra). Calculated mass of the -spectrin sequence (UniProtKB P11277) from Thr2-482 
Gln167 is 19,251 Da. CH1, CH2, calponin homology domains. c, Appearance of a ~17 kDa N-terminal 483 
fragment of -spectrin (arrowed) upon egress of mock-treated SERA6:loxP schizonts (reproducible in 4 484 
independent experiments). d, Pull-down of cytoskeletal components from soluble extracts of egressing 485 
SERA6:loxP schizonts. Annotated species, including co-precipitating -actin, were identified by LC-486 
MS/MS or Western blot (reproducible in 3 independent experiments). Peptide fingerprinting of the ~17 487 
kDa -spectrin CH1 domain was as in b. The presence of -spectrin and full-length and truncated -488 
spectrin in pull-downs from the -RAP extracts indicates their SERA6-dependent dissociation from the 489 
normally insoluble cytoskeleton. Antibody heavy and light chains, asterisked. e, Fate of -spectrin in 490 
SERA6:loxP schizonts following washing away a C2 block (control) or with additional treatment by the 491 
indicated disruption methods. Cleavage never occurred in the absence of SERA6 (Western blot 492 
representative of 2 independent experiments). f, Architecture of RBC cytoskeleton spectrin 493 
heterotetramer, comprising 2 antiparallel -spectrin heterodimers linked head-to-head (the right-494 
hand dimer is abbreviated for clarity) which cross-link -actin-containing junctional complexes24. 495 
Spectrin repeat domains are numbered. Other structural features and positions of epitopes recognised 496 
by mAbs B-1, B-2 and VD4 are indicated. g, Top, SERA6-dependent cleavage of -spectrin should release 497 
each end of the -spectrin tetramer from its cognate junctional complex. The cleaved CH1 domain 498 
may be released with actin still bound. Bottom, predicted global effect of SERA6-dependent cleavage 499 
on the cytoskeleton.  500 
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